Lectus Therapeutics Ltd. Secures £3Million Investment from the Wellcome Trust
Cambridge, UK 05 September 2007, Lectus Therapeutics Ltd, the drug discovery and development company focusing on next-generation ion channel modulators, announced today that the Wellcome Trust provided £3million of investment capital to fund a specific programme to identify new classes of selective potassium channel modulator drug candidates for the treatment of multiple sclerosis.